MAIA Bio to Acquire 180 Life Sciences for $1.5M
Ticker: MAIA · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biotechnology
TL;DR
MAIA Bio buying 180 Life Sciences for $1.5M cash/stock to boost pipeline.
AI Summary
MAIA Biotechnology, Inc. announced on March 5, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of 180 Life Sciences Corp. for approximately $1.5 million in cash and stock. This strategic acquisition is expected to enhance MAIA's pipeline and expand its market presence in the biotechnology sector.
Why It Matters
This acquisition could significantly bolster MAIA Biotechnology's drug development pipeline and market position, potentially leading to new therapeutic advancements.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and the possibility that the acquired assets may not perform as expected.
Key Numbers
- $1.5M — Acquisition Value (Total consideration for the acquisition of 180 Life Sciences Corp.)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- 180 Life Sciences Corp. (company) — Acquired entity
- $1.5 million (dollar_amount) — Acquisition price
- March 5, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report on other events, specifically the definitive agreement for MAIA Biotechnology, Inc. to acquire 180 Life Sciences Corp.
What is the total value of the acquisition of 180 Life Sciences Corp. by MAIA Biotechnology, Inc.?
The acquisition is valued at approximately $1.5 million, consisting of cash and stock.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on March 5, 2024.
What is the state of incorporation for MAIA Biotechnology, Inc.?
MAIA Biotechnology, Inc. is incorporated in Delaware.
What is the principal executive office address for MAIA Biotechnology, Inc.?
The principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Filing Stats: 829 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-03-06 08:00:38
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 25KB
- ex99-2.htm (EX-99.2) — 14KB
- 0001493152-24-008942.txt ( ) — 266KB
- maia-20240305.xsd (EX-101.SCH) — 3KB
- maia-20240305_lab.xml (EX-101.LAB) — 33KB
- maia-20240305_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 6, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3